. 2023 Nov 20;44(1):23–46. doi: 10.1002/cac2.12505

TABLE 1.

Results of phase III trials of adjuvant immunotherapy for resectable LA‐NSCLC.

Trial	No. of patients (stage)	Regimen	Median DFS (months) (HR; 95% CI)	Median OS (months) (HR; 95% CI)
IMpower010 [8] (NCT02486718)	413 (IIIA)	CT → atezolizumab vs. BSC × 1 year	Stage IIIA with PD‐L1 ≥ 1%: 42.3 vs. 26.7 (HR = 0.62; 95% CI = 0.42‐0.90); Stage IIIA: 32.3 vs. 29.7 (HR = 0.81; 95% CI = 0.61‐1.06)	Stage IIIA with PD‐L1 ≥ 1%: NA (HR = 0.71; 95% CI = 0.44‐1.15); Stage IIIA with PD‐L1 ≥ 50%: NA (HR = 0.30; 95% CI = 0.12‐0.74)
PEARLS/KEYNOTE‐ 091 [10] (NCT02504372)	177 (IIIA)	CT (optional) → Pembrolizumab vs. placebo × 1 year	NR (HR = 0.92; 95% CI = 0.69‐1.24)	NR

Trial

No. of patients (stage)

Regimen

Median DFS (months) (HR; 95% CI)

Median OS (months) (HR; 95% CI)

IMpower010 [8]

(NCT02486718)

413 (IIIA)

CT → atezolizumab vs. BSC × 1 year

Stage IIIA with PD‐L1 ≥ 1%: 42.3 vs. 26.7 (HR = 0.62; 95% CI = 0.42‐0.90);

Stage IIIA: 32.3 vs. 29.7 (HR = 0.81; 95% CI = 0.61‐1.06)

Stage IIIA with PD‐L1 ≥ 1%: NA (HR = 0.71; 95% CI = 0.44‐1.15);

Stage IIIA with PD‐L1 ≥ 50%: NA (HR = 0.30; 95% CI = 0.12‐0.74)

PEARLS/KEYNOTE‐

091 [10]

(NCT02504372)

177 (IIIA)

CT (optional) → Pembrolizumab vs. placebo × 1 year

NR (HR = 0.92; 95% CI = 0.69‐1.24)

Abbreviations: LA‐NSCLC, locally advanced‐non‐small cell lung cancer; CT, chemotherapy; BSC, best supportive care; HR, hazard ratio; CI, confidence interval; DFS, disease‐free survival; OS, overall survival; PD‐L1, programmed death‐ligand 1; NA, not available; NR, not reached.